Apolipoprotein B signal peptide polymorphism in patients with myocardial infarction and controls

1993 ◽  
Vol 90 (5) ◽  
Author(s):  
S. Visvikis ◽  
J.P. Cambou ◽  
D. Arveiler ◽  
A.E. Evans ◽  
H.J. Parra ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Signal Peptide ◽  
Apolipoprotein B ◽  
Signal Peptide Polymorphism

Association of the insertion/deletion gene polymorphism of the apolipoprotein B signal peptide with myocardial infarction

1998 ◽  
Vol 141 (1) ◽  
pp. 167-175 ◽  
Author(s):  
Andreas Gardemann ◽  
Dorothea Ohly ◽  
Monika Fink ◽  
Norbert Katz ◽  
Harald Tillmanns ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Gene Polymorphism ◽  
Signal Peptide ◽  
Apolipoprotein B

Apolipoprotein B signal peptide polymorphism in relation to lipids and diabetes in male CAD patients

2000 ◽  
Vol 152 (1) ◽  
pp. 257-258 ◽  
Author(s):  
Petr Beneš ◽  
Jan Mužı́k ◽  
Jaroslav Benedı́k ◽  
Lubomı́r Elbl ◽  
Vladimı́ra Znojil ◽  
...  
Keyword(s):  
Signal Peptide ◽  
Apolipoprotein B ◽  
Signal Peptide Polymorphism

scholarly journals Influence of Peripheral Artery Disease and Statin Therapy on Apolipoprotein Profiles

2013 ◽  
Vol 2013 ◽  
pp. 1-7
Author(s):  
Andrew W. Gardner ◽  
Petar Alaupovic ◽  
Donald E. Parker ◽  
Polly S. Montgomery ◽  
Omar L. Esponda ◽  
...  
Keyword(s):  
Physical Activity ◽  
Myocardial Infarction ◽  
Statin Therapy ◽  
Peripheral Artery Disease ◽  
Apolipoprotein B ◽  
Ldl Cholesterol ◽  
Risk Profile ◽  
Peripheral Artery ◽  
Artery Disease ◽  
Plasma Apolipoprotein

Apolipoprotein B is a stronger predictor of myocardial infarction than LDL cholesterol, and it is inversely related to physical activity and modifiable with exercise training. As such, apolipoprotein measures may be of particular relevance for subjects with PAD and claudication. We compared plasma apolipoprotein profiles in 29 subjects with peripheral artery disease (PAD) and intermittent claudication and in 39 control subjects. Furthermore, we compared the plasma apolipoprotein profiles of subjects with PAD either treated (n=17) or untreated (n=12) with statin medications. For the apolipoprotein subparticle analyses, subjects with PAD had higher age-adjusted Lp-B:C (P<0.05) and lower values of Lp-A-I:A-II (P<0.05) than controls. The PAD group taking statins had lower age-adjusted values for apoB (P<0.05), Lp-A-II:B:C:D:E (P<0.05), Lp-B:E + Lp-B:C:E (P<0.05), Lp-B:C (P<0.05), and Lp-A-I (P<0.05) than the untreated PAD group. Subjects with PAD have impaired apolipoprotein profiles than controls, characterized by Lp-B:C and Lp-A-I:A-II. Furthermore, subjects with PAD on statin medications have a more favorable risk profile, particularly noted in multiple apolipoprotein subparticles. The efficacy of statin therapy to improve cardiovascular risk appears more evident in the apolipoprotein sub-particle profile than in the more traditional lipid profile of subjects with PAD and claudication. This trial is registered with ClinicalTrials.govNCT00618670.

Xbal polymorphism in DNA at the apolipoprotein B locus is associated with myocardial infarction (MI)

2008 ◽  
Vol 44 (5) ◽  
pp. 241-248 ◽  
Author(s):  
M. Bøhn ◽  
A. Bakken ◽  
J. Erikssen ◽  
K. Berg
Keyword(s):  
Myocardial Infarction ◽  
Apolipoprotein B ◽  
B Locus

Glycated apolipoprotein B and myocardial infarction

2007 ◽  
Vol 17 (1) ◽  
pp. 6-12 ◽  
Author(s):  
G. Misciagna ◽  
G. Logroscino ◽  
G. De Michele ◽  
V. Guerra ◽  
A.M. Cisternino ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Apolipoprotein B
Sign in / Sign up

Export Citation Format

Share Document